Using domain switch chimeric antibodies, we confirm the important role of CH2 in complement activation. In addition, we demonstrate that the structures responsible for the differential ability of human IgG1 and IgG4 to activate complement are located at the COOH-terminal part (from residue 292 to 340) of the CH2 domain . The amino acids in CH2 that might be involved in complement interaction are discussed. While CH3 contributes to efficient complement activation, CH3 from IgG2 and CO IgG3 are equally effective.
T he ability to activate the complement cascade and thereby remove pathogenic agents is one of the most important effector functions of the antibody molecule . IgM and IgG are the only isotypes that activate the classical complement pathway. The four human IgG isotypes have very similar amino acid sequences, but differ markedly in their ability to activate complement. IgG3 and IgG1 are effective in activating complement, IgG2 fixes complement poorly, and IgG4 appears completely deficient in the ability to activate complement (1, 2) . An unresolved question is what amino acid differences determine this isotype-specific complement activation.
The hinge region shows the most sequence variation among the IgG isotypes (2, 3) . The hinge serves to both covalently link the two heavy chains and to endow the antibody molecule with segmental flexibility. We and others have shown that a hinge region is essential for Clq binding and complement activation (3, 4) . However, the flexibility of the hinge does not directly correlate with proficiency in complement activation, and replacing the rigid hinge of IgG4 with the flexible hinge of IgG3 did not result in an IgG4 molecule that can activate complement (3) . Therefore, while the hinge region may modulate the ability of the IgG molecule to activate complement, it does not appear to determine the isotypespecific differences.
Studies using antibody fragments suggested that the CH2 domain plays an important role in complement activation. Facb (IgG depleted of CH3) and CH2 fragments bind C1 and activate complement, while Fab and CH3 fragments did not show any activity (5-7). Moreover, aglycosylated IgG lacking carbohydrate in CH2 is unable to activate complement (8, 9) . While these experiments indicate that CH2 is primarily responsible for C1 binding and complement activation, CH2
is not the only structure required. IgG that lacks CH3 is only 50% as efficient in its ability to activate complement as intact IgG (5, 7). Moreover, while Glu 318, Lys 320, and Lys 322 in CH2 have been shown by in vitro mutagenesis to be important for complement activation (10), these residues are conserved among isotypes that do and do not activate complement, and thus could not determine the isotype-specific differences.
In this study, we have used domain exchange molecules to further investigate the residues responsible for the isotypespecific variation in complement activation. We confirm that CH2 appears to be the domain important for complement activation. Furthermore, we provide evidence that the 000H-terminal part (residues 292-340) of the CH2 domain contains the residues responsible for the isotype-specific differences in complement activation.
Materials and Methods
Construction of Chimeric IgG Molecules. The expressed VK and V genes from the mouse antidansyl (DNS) hybridoma 27-44 were joined to human C, in the pSV2AHneo expression vector and to human IgG C in the pSV2AHgpt vector, respectively (11) . As shown in Fig. 1 , a novel Pvul site was generated between exons in the IgG2 and IgG3 constant region genes such that each gene contains one Pvul site. The C1 and CH3 domain switch constant region genes were produced using clones with the appropriate Pvul sites. A Pvul site located between the hinge and C,,2 exons and a SacII site between the C2 and CH3 exons were used to generate the CH2 domain switch genes. IgG1 and IgG4 domain switch genes were generated using a SaclI site located within the CH2 exon. The domain switch heavy chain genes were cloned into the pSV20Hgpt expression vector and transfected with their specific (1) represent Pvul sites, which were introduced by using oligonucleotide linkers. All heavy chain constant regions were joined to the murine antidansyl variable region . Mutants with exon exchanges are given a four-digit name : the first digit refers to the subclass of the C1 domains, and the second, third, and fourth digits indicate the subclasses of the hinge, C.2, and C3 domains, respectively. WT indicates the wild-type gene.
light chain gene into the Ig nonproducing cell line, P3X63 Ag8.653, by either protoplast fusion or electroporation (12) . The clones were selected in medium containing the antibiotic G418 and screened for antibody production by ELISA. Chimeric antidansyl antibodies were purified by affinity chromatography. Complement-mediated Hemolysis. SRBC were coated with DNS/BSA and incubated with "Cr-sodium chromate (Amersham Corp ., Arlington Heights, IL). The free "Cr-sodium chromate was removed by washing the cells three times in 10 ml of fresh Gel-HBS buffer (0 .01 M Hepes, 0.15 M NaCl, 0.15 mM CaCl 2, 0.5 MM MgCl2, 0.1% gelatin, pH 7.4). Twofold serial dilutions of chimeric antibodies in Gel-HBS buffer were added to the roundbottomed, 96-well plate (Corning Glass Works, Corning, NY) in a volume of 50 P.1. 50 Al of 2% "Cr-loaded SRBC and 25 Al of 2 U CHso of guinea pig complement (Colorado Serum Co., Denver, CO) were added to each well sequentially. The plates were 1 10 too 
Results
A set of mouse-human chimeric antibodies having identical antigen-combining sites and light chain but with constant region domains switched between IgG2 and IgG3 or IgG1 and IgG4 were generated as described above. Fig . 1 is a schematic diagram of the genetic structures of the antibody constant regions .
To locate the domain responsible for complement activation, domains were changed between IgG2 and IgG3, and the ability of the resulting antibodies to mediate complementdependent cell lysis of SRBC coated with the hapten dansyl was measured . As shown in Fig . 2 A, replacement of the C 1 and C3 domains of IgG2 with the corresponding domains from IgG3, IgG(3-2-2-2), and IgG(2-2-2-3), did not increase the complement binding activity. However, IgG(2-2-3-2) containing the C.2 domain from IgG3 performs complement-mediated cell lysis almost as well as wild-type IgG3. Likewise, the replacement of the C2 domain of IgG3 with the corresponding domain from IgG2, IgG(3-3-2-3), completely abolished the capacity to fix complement (Fig.  2 B) . These results clearly demonstrate that the structures that determine the differing ability of IgG2 and IgG3 to activate complement are largely located in the C 2 domain.
To further localize the region of the C 2 domain that determines its ability to activate complement, a SacII site in the C 2 exon of the heavy chain genes of IgG1 and IgG4 was used to generate intra-domain switch antibodies between IgG1 and IgG4 (Fig . 1) . The SacII site is located at residue 292 in C.2 ; thus, IgG(1-1-1/4-4) has the COOH-terminal part (from residue 292-340) of the C2 domain and the C.3 domains from IgG4 . The same region in IgG(4-4-4/1-1) is from IgG1. The more sensitive complement consumption assay was used to measure the effect of domain switch between IgG1 and IgG4 in order to detect small amounts of residual activity. It was found that IgG(1-1-1/4-4) completely 1027 Tao et al . Brief Definitive Report lost its ability to activate complement ; in contrast, IgG(4-4-4/1-1) showed significant activity compared with wild-type IgG4 (Fig. 3) . These results indicate that residues 292-340 in C.2 contain amino acids determining the isotype-specific differences in complement activation .
Discussion
The human IgG molecules differ markedly in their ability to activate complement in spite of having very similar amino acid sequences . The important role of the C2 domain of IgG in complement activation was supported by earlier antibody fragmentation studies (5-7) . The contribution by C .3 was also indicated with the finding that C .3 could stabilize the conformation of Cl and protect it from attack by the C1 inhibitor (13) . The studies reported here show that it is the C,2 but not CF,3 that determines the human IgG isotype-specific differences in complement activation. Moreover, our studies now locate the important residues to the COOH terminus of the C2 domain between residues 292 and 340 . Within that region, IgG1 differs from IgG4 at only four residues : 296 (Tyr vs. Phe), 327 (Ala vs. Gly), 330 (Ala vs . Ser), and 331 (Pro vs. Ser). The locations of these amino acids in the three-dimensional structure of IgG1 Fc are shown in Fig . 4 . Using the nomenclature of Beale and Feinstein (15) , residues 330 and 331 are located on the Fy3 ß strand and fold into proximity with the previously identified 318-320-322 residues (10) . Therefore, these residues together may provide the binding site for C1q. The side chain of residue 327 is mostly buried inside the molecule and is probably not directly involved in Clq binding. However, the greater flexibility afforded by the Gly residue in IgG4 may change the conformation of the nearby Clq binding site and thus affect complement activation . Residue 296 is located on the surface of X face. It seems unlikely that a Clq molecule can bind the proposed binding site on Y face and residue 296 simultaneously. However, residue 296 in the other C 2 is quite accessible, as shown in Fig. 4 , and might contribute to the Clq binding site . The fact that both C.2 domains are required for C1 activation give indirect support for this possibility (5) .
Noteworthy is the fact that the IgG(4-4-4/1-1) molecule is slightly deficient in its ability to activate complement relative to wild-type IgG1. A significant difference between the two molecules is in the hinge region . It is quite possible that the rigid hinge of IgG4 impairs access to the Clq binding site thus decreasing the effectiveness of the molecule. We have observed a similar modulating effect of the hinge region on FcyRI binding (Canfield, S . M ., and S. L. Morrison, manuscript submitted for publication) . Alternatively, additional amino acid variation between the two isotypes within the C.2 NH2 terminal to the exchange point may further influence complement activation .
